CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION

The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CONLEY, Robert Russell, JOHNSON, Kirk Willis, DAVAR, Gudarz
Format:	Patent
Sprache:	eng
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	CONLEY, Robert Russell JOHNSON, Kirk Willis DAVAR, Gudarz
description	The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ZA202100666B</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ZA202100666B</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ZA202100666B3</originalsourceid><addsrcrecordid>eNrjZLBx9gjy9_N0VvDzdPcI8YlUcPEP9vRzV_B3U_BxDPb1dPEMcfRTcPMPUvD1dA9y9PRzVQgIcg1z9Qvx9PfjYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxUY5GBkaGBgZmZmZOxsSoAQANAymo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION</title><source>esp@cenet</source><creator>CONLEY, Robert Russell ; JOHNSON, Kirk Willis ; DAVAR, Gudarz</creator><creatorcontrib>CONLEY, Robert Russell ; JOHNSON, Kirk Willis ; DAVAR, Gudarz</creatorcontrib><description>The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.</description><language>eng</language><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240925&DB=EPODOC&CC=ZA&NR=202100666B$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240925&DB=EPODOC&CC=ZA&NR=202100666B$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CONLEY, Robert Russell</creatorcontrib><creatorcontrib>JOHNSON, Kirk Willis</creatorcontrib><creatorcontrib>DAVAR, Gudarz</creatorcontrib><title>CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION</title><description>The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLBx9gjy9_N0VvDzdPcI8YlUcPEP9vRzV_B3U_BxDPb1dPEMcfRTcPMPUvD1dA9y9PRzVQgIcg1z9Qvx9PfjYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxUY5GBkaGBgZmZmZOxsSoAQANAymo</recordid><startdate>20240925</startdate><enddate>20240925</enddate><creator>CONLEY, Robert Russell</creator><creator>JOHNSON, Kirk Willis</creator><creator>DAVAR, Gudarz</creator><scope>EVB</scope></search><sort><creationdate>20240925</creationdate><title>CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION</title><author>CONLEY, Robert Russell ; JOHNSON, Kirk Willis ; DAVAR, Gudarz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ZA202100666B3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>CONLEY, Robert Russell</creatorcontrib><creatorcontrib>JOHNSON, Kirk Willis</creatorcontrib><creatorcontrib>DAVAR, Gudarz</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CONLEY, Robert Russell</au><au>JOHNSON, Kirk Willis</au><au>DAVAR, Gudarz</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION</title><date>2024-09-25</date><risdate>2024</risdate><abstract>The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_ZA202100666B
source	esp@cenet
title	CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T11%3A10%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CONLEY,%20Robert%20Russell&rft.date=2024-09-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EZA202100666B%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true